Our Solutions
Cardiovascular Disease is the Leading Cause of Death in the U.S.
Cardiovascular disease (CVD) is responsible for nearly 1 in 3 deaths in the U.S. It claims more lives in the U.S. than all forms of cancer and accidental deaths combined.
CVD is not a single illness. It is a family of diseases that affect the heart and blood vessels, including coronary heart disease (CHD), stroke, heart failure and peripheral artery disease.
80-90% of Cardiovascular Disease is Estimated to be Preventable Through Early Detection and Proactive Management,,
Coronary Heart Disease is the Most Common Type of Cardiovascular Disease
CHD often develops silently over many years, and its first symptom may be a heart attack.
#2
cause of hospitalization and adds $13,000 more per year to patient healthcare costs,
1 in 20
U.S. adults aged over 20 years live with coronary heart disease
3-4 million
Americans are affected by Ischemia with No Obstructive Coronary Arteries (INOCA), a subset of CHD
For Many, a Heart Attack is the First Sign of Coronary Heart Disease
Heart attacks don't always announce themselves. Many occur without chest pain, especially in women and people with diabetes.
40 seconds
is how often someone in the U.S. experiences a heart attack
1 in 5
heart attacks are silent, occurring without warning
800,000+
is the number of heart attacks occurring annually
Waiting on Traditional Risk Factors and Obvious Symptoms to Develop Can Create Blind Spots
50%
of those with CHD do not have traditional risk factors
30-65%
of suspected ischemia cases reveal no obstructive disease
39%
is the average sensitivity of conventional risk calculators
Traditional Methods Fall Short in Personalizing Cardiovascular Care, Leaving Risk Underestimated and Disease Missed Altogether
Cardio Diagnostics' Solutions Redefine Prevention and Care by Leveraging Each Patient's Unique Molecular Biology
Our clinical solutions can reveal what traditional methods may miss by assessing a patient's epigenetic and genetic biomarkers. For non-clinical stakeholders, our population-level insights and biopharma research platform turn complex epigenetic and genetic data into clear, actionable insights.
Clinical Solutions
Population Health and Biopharma Solutions
Explore Tailored Resources Designed for
Patients, Providers, and Employers
- Centers for Disease Control and Prevention. "Heart Disease Facts." Centers for Disease Control and Prevention. https://www.cdc.gov/heart-disease/data-research/facts-stats/index.html
- American Heart Association. "Heart Disease Remains Leading Cause of Death as Key Health Risk Factors Continue to Rise." American Heart Association. https://newsroom.heart.org/news/heart-disease-remains-leading-cause-of-death-as-key-health-risk-factors-continue-to-rise
- World Heart Federation. "Prevention." World Heart Federation. Updated 2023. Accessed September 17, 2025. https://world-heart-federation.org/what-we-do/prevention/
- Cleveland Clinic. "Ninety Percent of Heart Disease Is Preventable Through Healthier Diet, Regular Exercise, and Not Smoking." Cleveland Clinic Newsroom. Published September 29, 2021. Accessed September 17, 2025. https://newsroom.clevelandclinic.org/2021/09/29/90-percent-of-heart-disease-is-preventable-through-healthier-diet-regular-exercise-and-not-smoking
- European Heart Network. "Cardiovascular Disease Risk Assessment Programmes." January 2021. Accessed September 17, 2025. https://ehnheart.org/wp-content/uploads/2023/08/EHN_CVD_Risk_Assessment_Programmes_Jan2021.pdf
- Haidar, A., A. Gajjar, R. V. Parikh, et al. "National Costs for Cardiovascular-Related Hospitalizations and Inpatient Procedures in the United States, 2016 to 2021." American Journal of Cardiology 234 (2025): 63–70. https://doi.org/10.1016/j.amjcard.2024.10.003
- Kazi, D. S., M. S. V. Elkind, A. Deutsch, et al. "Forecasting the Economic Burden of Cardiovascular Disease and Stroke in the United States Through 2050." Circulation 150, no. 4 (2024). https://doi.org/10.1161/cir.0000000000001258
- Polyak, A., J. Wei, M. Gulati, and N. Bairey Merz. "Clinical Aspects of Ischemia With No Obstructive Coronary Artery Disease (INOCA)." American Heart Journal Plus 37 (2024): 100352. https://doi.org/10.1016/j.ahjo.2023.100352
- Cardio Diagnostics, Inc. Internal Claims Data Analysis.
- Bastiany, A., C. Pacheco, T. Sedlak, J. Saw, S. E. S. Miner, S. Liu, A. Lavoie, D. H. Kim, M. Gulati, and M. M. Graham. "A Practical Approach to Invasive Testing in Ischemia With No Obstructive Coronary Arteries (INOCA)." CJC Open 4, no. 8 (2022): 709–720. https://doi.org/10.1016/j.cjco.2022.04.009
- Dogan, M. V., S. Knight, T. K. Dogan, K. U. Knowlton, and R. Philibert. "External Validation of Integrated Genetic-Epigenetic Biomarkers for Predicting Incident Coronary Heart Disease." Epigenomics 13, no. 14 (2021): 1137–1152. https://doi.org/10.2217/epi-2021-0123